Aromatase (CYP19A1) catalyzes the conversion of C 19 steroids to estrogens. Aromatase and its product estradiol (E 2 ) are crucial for the sexually dimorphic development of the fetal brain and the regulation of gonadotropin secretion and sexual interest in adults. The regulation of aromatase expression in the brain is not well understood. The aromatase (Cyp19a1) gene is selectively expressed in distinct neurons of the hypothalamus through a distal brain-specific promoter I.f located ;36 kb upstream of the coding region. Here, we investigated a short feedback effect of E 2 on aromatase mRNA expression and enzyme activity using estrogen receptor alpha (ESR1; also known as ERalpha)-positive or ESR1-negative mouse embryonic hypothalamic neuronal cell lines that express aromatase via promoter I.f. Estradiol regulated aromatase mRNA expression and enzyme activity in a time-and dose-dependent manner, whereas an E 2 antagonist reversed these effects. The nucleotide À200/À1 region of promoter I.f conferred E 2 responsiveness. Two activator protein 1 (AP-1) elements in this region were essential for induction of promoter activity by E 2 . ESR1 and JUN (c-Jun) bound to these AP-1 motifs in intact cells and under cell-free conditions. The addition of an ESR1 mutant that interacts with JUN but not directly with DNA enhanced E 2 -dependent promoter I.f activity. Independently, we demonstrated an interaction between ESR1 and JUN in hypothalamic cells.
INTRODUCTION
Estrogen is produced in the ovary, testis, and brain. Besides its well-established biologic effects on reproductive neuroendocrine function and recovery after brain injury, estrogen also exerts a wide variety of actions on regions of the developing and adult brain that influence higher cognitive functions, pain mechanisms, fine motor skills, susceptibility to seizures, mood, temperature regulation, and sleep [1, 2] . Estrogen biosynthesis is dependent on the facilitation of the entry of cholesterol into mitochondria followed by six enzymatic steps. Aromatase is the key enzyme and catalyzes the final step; that is, the conversion of C 19 steroids to estrone or estradiol (E 2 ) [3] [4] [5] .
A single gene, Cyp19a1, encodes aromatase, the inhibition of which effectively eliminates estrogen production in the entire body [6, 7] . The mouse aromatase gene is located on the long arm of chromosome 9. This gene spans a region that consists of a 30-kb coding region and a minimum of 75 kb of regulatory region (at least 105-kb total length) [8] . The downstream 30-kb coding region comprises nine coding exons (II-X) [9] . The upstream 40-kb portion of the gene contains multiple promoters that direct transcription of alternative first exons, giving rise to aromatase mRNA species with unique 5 0 -untranslated regions. This region contains four promoters regulated in a partly tissue-specific manner: the proximal gonad-specific promoter and the far distal adipose promoter, which lies some 75 kb upstream of the ATG translational start site of the coding exon II, mark the ends of this regulatory region. Brain-specific promoter I.f is located at approximately 36 kb upstream of the coding region [8, 10, 11] .
In the vertebrate brain, aromatase is expressed primarily in the hypothalamus, hippocampus, and amygdala via a highly conserved promoter I.f [12, 13] . Aromatase expression in the hypothalamus is localized primarily in the medial preoptic area and the ventromedial nucleus of the hypothalamus (VMH), which govern various reproductive functions of both sexes in different species [14] [15] [16] [17] .
The physiological roles of aromatase in the brain were suggested by studies on mice with a disrupted aromatase gene (Cyp19a1 KO) and men with inactivating mutations of the aromatase gene [6, 18] . In both cases, aromatase deficiency was associated with increased testosterone and gonadotropin levels, indicating that aromatase and E 2 were essential for regulating gonadotropin secretion. Additionally, sexual activity and desire were significantly decreased in aromatase-deficient men and male mice, and they could be restored by E 2 treatment, thus revealing essential roles for aromatase and E 2 in regulating sexual behavior [7, 19, 20] .
The signaling pathways or molecular mechanisms that regulate the brain-specific aromatase promoter I.f are not well understood. Several groups of investigators found that protein kinases A and C and cAMP regulate aromatase expression and activity in the brain [21, 22] . Other groups showed that testosterone also upregulates aromatase mRNA and enzyme activity in the brain [17, [23] [24] [25] [26] . Moreover, E 2 was found to upregulate or downregulate hypothalamic aromatase mRNA and enzyme activity under both in vivo and in vitro circumstances [17, 25, 27, 28] . None of these studies, however, provided a connection between aromatase expression and the regulation of promoter I.f in brain tissue. In the only relevant publication, it was reported that the cis-regulatory element stress response element regulated the aromatase promoter I.f; however, neither the transcription factors nor any exogenous hormones responsible for this regulation have been reported [12] . We conducted this study to demonstrate the regulation of hypothalamic aromatase activity by E 2 via the brain-specific aromatase promoter I.f and to identify the cis-regulatory elements and transcriptional activators involved.
MATERIALS AND METHODS

Cell Culture
Mouse embryonic hypothalamic neuronal cell lines N38 and N42 were purchased from Cellutions Biosystems Inc. (Toronto, ON, Canada) [29] and were cultured in Dulbecco modified Eagle medium (DMEM; Gibco, New York, NY) supplemented with 10% fetal bovine serum (FBS; Gibco) and 1% penicillin-streptomycin (Gibco). The cells were studied at passages 15 to 16. After 24 h of serum starvation, cells were treated with various doses of 17b-estradiol (Sigma-Aldrich, St. Louis, MO) for different times.
RNA Isolation and Real-Time RT-PCR
Hypothalamic cells were treated with either vehicle (ethanol) or 10 À7 , 10 À8 , or 10
À9 M E 2 , and total RNA was extracted after 6, 12, and 24 h of treatment using TRI reagent (Sigma) per the manufacturer's instructions. On column, DNAse digestion was carried out using a DNAse I kit (Qiagen, Valencia, CA). The integrity of the isolated RNA was verified by running 5 lg of total RNA on a 1% formaldehyde gel. Five micrograms of total RNA from vehicle or E 2 -treated hypothalamic cells was used for reverse transcription in a final volume of 20 ll using Superscript III First Strand RT synthesis kit (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. Five microliters of cDNA was used for real-time RT-PCR (Taqman real-time primers and probe for aromatase were designed using ABI primer express software 3.0) on an Applied Biosystems 7000 Sequence Detection System (Applied Biosystems, Foster City, CA). The reactions were carried out using the ABI Taqman assay system for the aromatase promoter I.f-specific sequence (untranslated first exon I.f) and power SYBR green for the aromatase coding region according to the manufacturer's protocol. The primers and probes for aromatase (Cyp19a1) and Esr1 are as follows. Taqman Assay primers for Cyp19a1 exon I.f:
0 . Each contained a 6-carboxy-fluorescein phosphoramidite (FAM dye; Applied Biosystems, Foster City, CA) label at the 5 0 end and a minor groove binder and nonfluorescent quencher at the 3 0 end and were designed to hybridize to the exon I.f-exon II junction. SYBR green assay primers for Cyp19a1: forward 5 0 -tgtgttgaccctcatgagaca-3 0 , reverse 5 0 -cttgacggatcgttcatacttc-3 0 ; for Esr1: forward 5 0 -atgaaaggcggcatacggaaag-3 0 , reverse 5 0 -cacccatttcatttcggccttc-3 0 ; and for Gapdh: forward 5 0 -accacagtccatgccatcac-3 0 , reverse 5 0 -tccaccaccctgttgctgta-3 0 . Conventional PCR primers for Esr1: forward 5 0 -tccttctagacccttcagtgaagcc-3 0 , reverse 5 0 -acatgtcaaagatctccaccatgcc-3 0 . Polymerase chain reaction was carried out in triplicate in a 50-ll reaction volume using SYBR green PCR mix. The reactions were incubated at 508C for 2 min and 958C for 10 min, followed by 40 cycles of 958C for 15 sec and 608C for 1 min. The threshold cycle (C T ) is defined as the fractional cycle number at which the fluorescence passes the fixed threshold. Relative mRNA units were calculated from C T values as described previously [30] . All RNA samples were normalized to the expression levels of a glyceraldehyde-3-phosphate dehydrogenase (Gapdh) gene endogenous control. No-template and no-RT controls were used to ensure the absence of genomic DNA and reaction specificity. Three independent experiments were performed to demonstrate reproducibility. Real-time RT-PCR product specificity was confirmed by meltcurve analysis, gel electrophoresis, and product sequencing.
Aromatase Enzyme Activity Assay
The aromatase enzyme activity within hypothalamic cells was measured by [ 3 H]water release assay, which is routinely used in our laboratory [31] -1b]androstenedione were removed from the mixture by first mixing with 4 ml of chloroform followed by centrifugation at 3000 rpm. The upper aqueous layer was removed and mixed with dextran-coated charcoal (1% wt/vol). Charcoal was precipitated by centrifugation. From each tube, 2 ml of clear solution was placed into a scintillation vial containing 10 ml of scintillation fluid and was counted in a scintillation counter (LS 6500; Beckman Coulter Inc., Fullerton, CA).
Immunoblotting
Hypothalamic neuronal cell lines were cultured in 150-mm dishes in DMEM containing 10% FBS until reaching 80% confluency. Total protein was extracted from cells using the M-PER mammalian protein extraction reagent (Pierce, Rockford, IL). Protein concentration was determined using the BCA protein assay kit (Pierce). Fifty micrograms of cell lysate was mixed with 23 Laemmli Sample Buffer (Bio-Rad Laboratories, Hercules, CA) and fractionated in 4%-15% SDS-PAGE. Proteins from the gel were transferred to a nitrocellulose membrane. The membranes were then incubated with mouse estrogen receptor alpha (ESR1) antibody (1:1000 dilution; Upstate, Charlottesville, VA) in 5% milk solution overnight at 48C. The membrane was washed for 30 min then incubated with anti-rabbit immunoglobulin G (IgG)-peroxidase conjugate (Upstate) as a secondary antibody (1:3000 dilution). Incubation with the secondary antibody was performed at room temperature for 1 h. The signal was detected using SuperSignal West Femto maximum-sensitivity substrate chemiluminescence kit (Pierce) according to the manufacturer's instructions and exposed to BioMax ML X-ray film (Eastman Kodak, Rochester, NY) for 1-5 min. Then, the membranes were stripped of the first antibody and probed with anti-actin, followed by the same signal detection procedure described above.
Transient Transfections and Luciferase Assays
Transient transfection of N42 hypothalamic neuronal cell lines was carried out in 12-well plates with Fugene HD transfection reagent (Roche Diagnostics, Pleasanton, CA) with the following plasmids: 1) 1 lg of pGL3-basic luciferase reporter plasmid containing the promoter I.f nt À1000/À1 fragment, progressively truncated promoter I.f fragments (À700,À500,À200,À50), or ntÀ200/À1 constructs with mutations in the activator protein 1 (AP-1) cis-acting elements; 2) 50 ng of pRL-TK plasmid as an internal control (Promega, Madison, WI); and 3) 1 lg of wild-type mouse ESR1 or DNA-binding domain mutant ESR1-AA expression vectors. Cells were serum deprived 1 day before transfection. Wildtype ESR1 or ESR1-AA expression vectors were cotransfected with the ntÀ200/ À1 promoter-luciferase reporter construct in equal amounts. Twenty-four hours after transfection, N42 cells were treated either with vehicle (ethanol) or 10 À7 M E 2 for 24 h. At the end of the treatment period, transfected cells were washed twice in PBS and lysed in 250 ll of lysis buffer (0.1 M potassium phosphate [pH 7.8], 1% Triton X-100, 1 mM dithiothreitol, and 2 mM ethylenediaminetetraacetic acid [EDTA]). Luciferase assays were performed with 20 ll of cell lysate employing a Dual-Luciferase Reporter Assay System kit (Promega). Luminescence was measured with a LUMAT LB9507 luminometer (EG&G Berthold, Bad Wildbad, Germany). Results are presented as the average of luciferase activity from triplicate experiments and expressed as the ratio to the internal standard Renilla luciferase. Plasmids used in transfection experiments were purified using an EndoFree Plasmid Isolation Kit (Qiagen), and their purity was verified by spectrophotometry and agarose gel electrophoresis. All transfection assays were performed using equimolar amounts of plasmids.
Site-Directed Mutagenesis
The putative AP-1 cis-acting elements were mutated using QuickChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) according to the AROMATASE PROMOTER I.f AND ESTROGEN RECEPTOR ALPHA manufacturer's instructions. A chimeric luciferase construct containing the nt À200/À1 region of promoter I.f was used as a template for site-directed mutagenesis. Briefly, a PCR reaction using the DNA template (50 ng), mutagenesis primers (125 ng), deoxyribonucleotide triphosphate, and PfuTurbo DNA polymerase (2.5 U/ll) was carried out for 15 cycles at 958C for 30 sec, 558C for 60 sec, and 688C for 10 min. After the reaction, DpnI restriction enzyme (10 U/ll) was added to the PCR products and incubated at 378C for 60 min to eliminate the native DNA template. The mutagenesis reaction was then used to transform DH-5a-competent cells. Desired mutations were confirmed by DNA sequencing (Northwestern University sequencing facility). The oligonucleotides used for mutagenesis, with the mutated nucleotides underlined, are as follows (the complementary strand sequence is not shown):
Chromatin-Immunoprecipitation-PCR Assay
The chromatin-immunoprecipitation PCR (ChIP) assay was performed with the Acetyl-Histone H4 Immunoprecipitation (ChIP) Assay Kit (Upstate Biotechnology, Lake Placid, NY) following the manufacturer's instructions with minor modifications. Briefly, after reaching 80%-90% confluency in 150-mm culture dishes (;2 3 10 7 cells), hypothalamic cells were serum starved for 24 h, then treated with either vehicle (ethanol) or 10 À7 M E 2 for 6 h. Cells were then cross-linked with 1% formaldehyde for 10 min at room temperature on an orbital shaker, followed by the addition of 1 M glycine for 5 min. Cells were washed with cold PBS containing protease inhibitors and were lysed using a lysis buffer (50 mM Tris-HCl, pH 8.1, containing 1% SDS and 10 mM EDTA). The cells were sheared using a Sonic Dismembrator Model 100 (Fisher Scientific, Hampton, NH) at 70% maximum amplitude (15 sec on, 60 sec off) for five pulses to obtain DNA fragments in the range of 200 to 1000 bp. The sonicated cell supernatant was diluted 10-fold in ChIP dilution buffer, and 40 ll was used as input DNA (positive control). Precleared chromatin was used for immunoprecipitation (IP) reactions with 5 lg of the following specific antibodies: ESR1 (Upstate), c-Jun (JUN; Calbiochem, San Diego, CA), c-Fos (FOS; Calbiochem), or nonspecific rabbit IgG (Upstate). The reactions were incubated on a rotator overnight at 48C. The immune complexes were collected using protein A-agarose/DNA beads and washed five times using low salt, high salt, and lithium chloride, and washed twice with Tris-EDTA buffers. The absorbed immune complexes were recovered by incubation with elution buffer (1% SDS and 0.1 M NaHCO 3 ). Part of the eluate was saved and checked for the targeted protein IP by immunoblotting (IB). After reverse cross-linking at 658C for 4 h, the genomic DNA was purified using a DNA purification kit (Qiagen). The promoter I.f region was scanned for possible ESR1 binding by PCR amplification using seven different pairs of primer sets representing the nt À1000/À1 region with ;150-bp intervals. The PCR reactions were optimized according to each primer set, but the best amplification conditions for all primer sets were the following: 35 cycles (30 sec of denaturation at 948C, 1 min of annealing at 57.58C, and 1 min of elongation at 728C). Chip primers were designed using the Primer3 Software (http://frodo.wi.mit.edu/primer3/input. htm) and are as follows: forward 5 0 -ggcttctcttggtacgctga-3 0 and reverse 5 0 -ttgttgctaagagatcagttgctt-3 0 , which amplified the nt À190/À40 region of promoter I.f to yield a 150-bp amplicon; forward 5 0 -accacagagagtgaaagtttgag-3 0 and reverse 5 0 -gcgtaccaagagaagccaat-3 0 , which amplified the nt À334/À173 region of promoter I.f to yield a 162-bp amplicon; forward 5 0 -gcattcaagtttgctcagagg-3 0 and reverse 5 0 -ttcttttgatggggttgcac-3 0 , which amplified the nt À431/ À281 region of promoter I.f to yield a 151-bp amplicon; forward 5 0 -cctgcctaaaggctaagatcc-3 0 and reverse 5 0 -acacacatacacctctgagcaaa-3 0 , which amplified the nt À549/À399 region of promoter I.f to yield a 151-bp amplicon; forward 5 0 -cccaaaccttatcaacttagcc-3 0 and reverse 5 0 -ggatcttagcctttaggcaggt-3 0 , which amplified the nt À692/À528 region of promoter I.f to yield a 165-bp amplicon; forward 5 0 -tgagatgtaaacattatgtgtgtgct-3 0 and reverse 5 0 -ggtttgggtttaggggaat-3 0 , which amplified the nt À793/À685 region of promoter I.f to yield a 109-bp amplicon; and forward 5 0 -agcagagatggcttgtggtt-3 0 and reverse 5 0 -gcacacacataatgtttacatctca-3 0 , which amplified the nt À925/À768 region of promoter I.f to yield a 158-bp amplicon. All ChIP buffers used in this protocol contained a 13 protease inhibitor cocktail (Sigma).
Electrophoretic Mobility Shift Assay
Nuclear protein extracts used for electrophoretic mobility shift assay (EMSA) were prepared as described previously [32, 33] . The sequences of the double-stranded oligonucleotides used for EMSA were: 5 0 -GCTGAGATC-TATTACAAAGCCAAAC-3 0 , which is identical to a 25-bp-long sequence (nt À175/À151) within promoter I.f and contains one AP-1 cis-acting element at nt À166/À160; and 5 0 -AGATGAAATGACACAATTTGGTTAT-3 0 , which is identical to a 25-bp-long sequence (nt À138/À114) within promoter I.f and contains one AP-1 cis-acting element at nt À130/À124. The mutant forms of the oligonucleotides, with the mutated bases underlined, were: 5 0 -GCTGA-GATCTGGGACAAAGCCAAAC-3 0 and 5 0 -AGATGAAATTTTACAAT-TTGGTTAT-3 0 . All oligonucleotides were synthesized by Integrated DNA Technologies (Coralville, IA). The sequence for the AP-1 cis-acting element consensus sequence oligonucleotide was 5 0 -CGCTTGATGACTCAGCCGG-GA-3 0 , and its mutant form, with the mutated bases underlined, was 5 0 -CGCTTGATGACTTGGCCGGAA-3 0 . Both oligonucleotides were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). After renaturing two singlestranded oligonucleotides to a duplex oligonucleotide, we end labeled the AP-1 consensus cis-acting element and promoter I.f putative AP-1 cis-acting element containing oligonucleotides with [c-32 P]ATP using T4 kinase. Free [c-32 P]ATP was removed by Bio-Spin 6 chromatography columns (Bio-Rad). Briefly, 4-lg samples of nuclear extracts were incubated with the radiolabeled doublestranded oligonucleotide probe (50 0000 cpm per reaction) for 20 min at room temperature in a reaction buffer containing 20 mM HEPES (pH 7.6), 75 mM KCl, 0.2 mM EDTA, 20% glycerol, and 2 lg of poly(dI-dC)-poly(dI-dC) as a nonspecific competitor. For competition EMSA, a nonradiolabeled doublestranded oligonucleotide was added simultaneously with the labeled probe at 1003 concentration. Immunodepletion was performed after the addition of 2 lg of an antibody against JUN (Cell Signaling Technology, Danvers, MA), ESR1, or IgG to the binding reaction, followed by a 30-min incubation at room temperature before electrophoresis. Then, protein-DNA complexes were resolved on 6% nondenaturing polyacrylamide gels with 0.53 Tris-borate-EDTA running buffer. Gels were covered with cellophane membranes (BioRad) and dried on a Bio-Rad gel air dryer for 2 h. Gels were then exposed to BioMax ML x-ray film overnight for visualization.
IP/IB Assay
Immunoprecipitation was performed with nuclear protein preparations of hypothalamic cells prepared by N-PER nuclear extraction kit (Pierce). Protein concentration was determined using BCA protein assay kit according to the manufacturer's instructions. Nuclear protein preparations (200 lg) were Proteins were transferred to nitrocellulose membrane and were probed with antibodies against c-Jun or ESR1. We performed the IP assay for ESR1 and IB assay for JUN, and vice versa, to confirm the ESR1-JUN interaction.
Small-Interfering RNA
Nonspecific (NS) small-interfering RNA (siRNA) and ESR1 siRNA were purchased from Dharmacon (Chicago, IL). ESR1 knockdown was verified by real-time RT-PCR and IB. One day before transfection, hypothalamic cells were plated in six-well plates to achieve 50% confluency at the time of transfection, and they were then transfected with 100 nM NS siRNA or ESR1 siRNA in triplicate using lipofectamide RNAiMAX reagent (Invitrogen Life Technologies Inc., New York, NY) according to the manufacturer's protocol. Forty-eight hours after transfection, cells were serum starved for 24 h, followed by treatment with 10
À7 M E 2 for 6 h. Total mRNA was extracted for real-time RT-PCR assay, and total protein was isolated by M-PER reagent for immunoblot analysis.
Statistical Analysis
Statistical analyses were performed by Welch paired t-test and one-way ANOVA followed by Tukey multiple-comparisons test using the StatView 5.0 statistical software package (SAS Institute, Cary, NC). Significance was determined at a ¼ 0.05 and b ¼ 0.20. The values for mRNA and aromatase activity were provided as the mean 6 SEM.
RESULTS
Determination of Aromatase and Esr1 Expression Levels in N42 and N38 Hypothalamic Neuronal Cell Lines
Conventional RT-PCR, real-time RT-PCR, and IB analyses were performed to measure aromatase and Esr1 expression in N42 and N38 hypothalamic neuronal cell lines. Both promoter I.f-driven aromatase expression (Fig. 1A) and Esr1 expression (Fig. 1, B and C) were remarkably higher in N42 cells
FIG. 2.
Estradiol regulates aromatase mRNA expression and enzyme activity in N42, but not N38, hypothalamic cells. A) Real-time RT-PCR was performed to measure aromatase mRNA expression after 6, 12, and 24 h of E 2 (10 À7 M) treatment. Aromatase mRNA levels were normalized to Gapdh mRNA levels. Results are expressed as the mean 6 SEM (n ¼ 3); **P , 0.01, paired t-test. Aromatase activity assays were performed in N42 (B) and N38 (C) hypothalamic cells after 6, 12, and 24 h of E 2 (10 À7 M) treatment. The results are expressed as the mean 6 SEM (n ¼ 3); **P , 0.01, paired t-test. Aromatase enzyme activity in each neuronal line treated with the aromatase enzyme inhibitor letrozole (LET) was undetectable (data not shown).
FIG. 3. The E 2 antagonist ICI inhibits baseline and E 2 -induced aromatase mRNA expression and enzyme activity in N42 hypothalamic cells. A)
Real-time RT-PCR was performed after cells were incubated in the presence or absence of 10 À7 M E 2 plus or minus 10 À5 M ICI for 6 h. Aromatase mRNA levels were normalized to Gapdh mRNA levels. The results are expressed as the mean 6 SEM (n ¼ 3); **P , 0.01, ANOVA. B) Aromatase activity assays were performed to measure enzyme activity in cells incubated in the presence or absence of 10 À7 M E 2 plus or minus 10 À5 M ICI for 6 h. The results are expressed as the mean 6 SEM (n ¼ 3); **P , 0.01, ANOVA. Aromatase activity in the N42 neuronal line treated with the aromatase enzyme inhibitor LET was undetectable (data not shown).
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compared with N38 cells. These results were reproducibly observed in three independent experiments.
Effect of E 2 on Aromatase mRNA Expression and Enzyme Activity
Real-time RT-PCR and aromatase enzyme activity assays were performed to determine whether E 2 had any effects on aromatase mRNA expression and enzyme activity. We treated N42 and N38 hypothalamic cells with 10 À7 M, 10 À8 M, and 10 À9 M E 2 for 6, 12, and 24 h. At 10 À8 M and 10 À9 M, E 2 had no effect on aromatase mRNA expression and enzyme activity in either cell line (data not shown). Estradiol at 10 À7 M, however, had a biphasic effect on aromatase mRNA expression and enzyme activity in N42 hypothalamic cells (Fig. 2, A and  B) . In N38 hypothalamic cells, 10
À7 M E 2 had no effect on aromatase mRNA expression or enzyme activity at any time point (Fig. 2C) . Our results suggested that high baseline levels of aromatase expression with a remarkable response to E 2 in N42 cells compared with lower aromatase expression without any E 2 response in N38 cells may, in part, be due to much higher ESR1 levels in N42 cells.
The ESR Antagonist ICI 182,780 Inhibits E 2 -Induced Aromatase mRNA Expression and Enzyme Activity
To clarify whether the mechanism of E 2 action on aromatase expression and enzyme activity is ESR dependent, we treated N42 hypothalamic cells with the E 2 antagonist ICI 182, 780   FIG. 4 . AP-1 cis-regulatory elements within the nt À200/À1 region of promoter I.f are essential for E 2 -dependent induction of aromatase expression in N42 hypothalamic cells. A) Serial deletion analysis was performed to localize the E 2 -responsive regions of aromatase promoter I.f. The promoter I.f-luciferase (LUC) reporter constructs were named according to the nucleotide positions of their 5 0 termini. All constructs were transiently transfected into N42 hypothalamic cells. Luciferase assays were performed a minimum of three times in the presence or absence of 10 À7 M E 2 . Mean luciferase activity of each construct is given relative to the nt À1000/À1 promoter-luciferase reporter construct. Summary data for three independent experiments are shown. Results are expressed as the mean 6 SEM (**P , 0.01, paired t-test). B) Mutational analysis of promoter I.f was performed to verify functional cis-regulatory elements. Substitution mutations were made within two putative AP-1 cisregulatory elements in the À200/À1 promoter-luciferase reporters. Constructs were transiently cotransfected with ESR1 expression vector into N42 hypothalamic cells, and luciferase activities were measured after treatment with vehicle or 10 À7 M E 2 . Results shown are the mean 6 SEM of three independent experiments (**P , 0.01, ANOVA).
FIG. 5. ChIP analysis reveals ESR1
and JUN, but not FOS, bind to promoter I.f in N42 hypothalamic cells. We performed ChIP assays using N42 hypothalamic cell extracts treated with vehicle or 10 À7 M E 2 for 6 h. Sonicated cell supernatant was used as input DNA (positive control). Precleared chromatin was used for IP reactions with a rabbit polyclonal antibody directed against human (A) ESR1 and (B) JUN or FOS, as well as normal rabbit IgG. ESR1 was recruited to the E 2 -responsive nt À193/À47 but not to a more distal (nt À925/À768) region (see Fig. 4 ). Estradiol induced the recruitment of JUN but not FOS to the nt À193/À47 region. The figures represent one of three independently performed experiments.
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(ICI). Treatment with ICI only reduced baseline aromatase mRNA levels significantly (Fig. 3A) . ICI interfered with E 2 -induced aromatase mRNA expression and enzyme activity, as assessed by real-time RT-PCR and aromatase enzyme activity assays (Fig. 3, A and B) .
The nt À200/À1 Region of Promoter I.f Confers Responsiveness to E 2
To identify specific cis-regulatory elements within the À1000/À1 region of aromatase promoter I.f, we generated a series of truncated reporter constructs and transiently transfected them into N42 hypothalamic cells. The À500/À1 construct conferred the highest baseline promoter activity, suggesting that À500/À200-bp region contains critical cisregulatory elements for baseline gene expression (Fig. 4A) . On the other hand, only the nt À200/À1 promoter-luciferase reporter construct was responsive to E 2 (;2.3-fold induction; Fig. 4A ).
It was proposed that ESR1 exerts some of its genomic actions via indirect binding to AP-1 or SP1 motifs in target promoters [34, 35] . ESR1 binding to AP-1 cis-regulatory elements may occur as a complex with JUN and/or FOS transcription factors [35] . We could not identify any palindromic estrogen response elements (EREs) or ERE half-sites in the nt À1000/À1 region, but there were two putative AP-1 motifs at nt À166/À160 and nt À130/À124. Introduction of substitution mutations into these putative AP-1 motifs abolished promoter activity of the nt À200/À1 promoterreporter luciferase construct, even in the presence of overexpressed ESR1 (Fig. 4B ).
ESR1 and JUN, but Not FOS, Interact with Promoter I.f
We performed ChIP assays to confirm that ESR1 or JUN binds to aromatase promoter I.f. We used seven different sets of overlapping primer pairs representing the nt À1000/À1 region of promoter I.f, with ;150-bp intervals. As shown in Figure 5A , the most consistent and intense transcription factor binding occurred at the nt À200/À1 region. Under serumstarved conditions, we observed ESR1 binding in N42 but not in N38 hypothalamic cells, and binding of ESR1 to the nt FIG. 6. Putative AP-1 sites at nt À130/À124 and nt À166/À160 regions of promoter I.f are the major c-Jun-ESR1 binding sites. An EMSA was used to visualize JUN and ESR1 binding to AP-1 sites within promoter I.f. The EMSAs were performed using 5 lg of nuclear extract from N42 hypothalamic cells treated with E2 (10À7 M; 6 h) and radiolabeled oligonucleotide probes containing critical AP-1 sites and flanking sequences. A) Binding to an oligonucleotide identical to the nt À138/À114 sequence in promoter I.f and containing the nt À130/À124 AP-1 element (native; lane 2). Competition studies were performed using 100-fold excess unlabeled wild-type (consensus; lanes 3 and 4) or native oligonucleotides (lane 5) or mutant native oligonucleotides (lane 6). Immunodepletion of complexes was performed using 2 lg of anti-c-Jun (lanes 7 and 9) or 0.5 lg of anti-ESR1 (lanes 8 and 10) antibody (ab). Normal rabbit IgG was added as a negative control (lanes 11 and 12) . B) Binding to an oligonucleotide identical to the nt À175/À151 sequence in promoter I.f and containing the nt À166/À160 AP-1 element (native) (lane 2). Competition studies were performed using 100-fold excess unlabeled consensus or native probes (lanes 5 and 7) or mutant consensus or mutant native probes (lanes 6 and 8). Immunodepletion of complexes was performed using 2 lg of anti-c-Jun (lanes 10 and 12) or 0.5 lg of anti-ESR1 (lanes 9 and 11) antibody (ab). Normal rabbit IgG was added as a negative control (lanes 13 and 14) . Black arrows indicate JUN-ESR1 complexes, and white arrows indicate supershifted complexes by either c-Jun or ESR1 antibodies. The figures represent one of three independently performed experiments.
AROMATASE PROMOTER I.f AND ESTROGEN RECEPTOR ALPHA
À193/À47 region was enhanced by E 2 treatment (10 À7 M; 6 h) in both N42 and N38 hypothalamic cells. Estradiol-induced recruitment of ESR1 was observed at the E 2 -responsive nt À193À47 but not at a more distal (nt À925/À768) region (Fig.  4) . We also found that JUN, but not FOS, bound to the nt À193/À47 region in N42 hypothalamic cells, and JUN bound only in the presence of E 2 (Fig. 5B) .
The nt À130/À124 and nt À166/À160 Regions of Promoter I.f Are the Major ESR1-JUN Binding Sites
To determine whether the putative AP-1 cis-acting elements at nt À130/À124 or nt À166/À160 interact with JUN and ESR1, we performed EMSAs using probes representing either AP-1 site in the I.f promoter. A probe representing the consensus AP-1 sequence was used as a control. Nuclear protein extracts prepared from E 2 -treated (10 À7 M; 6 h) N42 hypothalamic cells formed complexes on DNA fragments containing the nt À130/ À124 (Fig. 6A ) and the nt À166/À160 (Fig. 6B) regions of the aromatase I.f promoter. Antibodies against ESR1 or JUN immunodepleted and supershifted the specific complexes formed on the probes containing the nt À130/À124 or nt À166/À160 sequences (Fig. 6 ).
ESR1 DNA-Binding Domain Is Not Necessary for ESR1-Mediated Regulation of Aromatase mRNA Expression
To determine whether the ESR1 DNA-binding domain is required for ESR1 action on aromatase mRNA expression, we cotransfected N42 hypothalamic cells with an nt À200/À1 promoter I.f-luciferase reporter and expression plasmids containing wild-type ESR1 or ESR1 carrying a mutation within the DNA-binding domain. Cells were treated with 10 À7 M E 2 . Estradiol-stimulated I.f promoter activity increased in the presence of overexpressed ESR1 or ESR1 with a defective DNA-binding domain (ESR1-AA) but not in the presence of the empty expression vector (Fig. 7) .
ESR1 and JUN Form a Complex
We performed IP/IB assays to determine whether ESR1 forms complexes with JUN or FOS in E 2 -treated hypothalamic N42 cells. We performed IP using antibodies against JUN or FOS, followed by IB using an antibody against ESR1. After 6 h of E 2 (10 À7 M) treatment, ESR1 formed a complex with JUN but not with FOS (Fig. 8A) . We verified these findings by reversing the order in which the antibodies were used. Immunoprecipitation with a human antibody raised in mouse (mESR1) or rabbit (rESR1) followed by IP using an antibody against JUN confirmed formation of a complex between ESR1 and JUN in N42 hypothalamic cells (Fig. 8B ).
E 2 -Stimulated Aromatase Expression Is Mediated by ESR1
The siRNA technology was used to determine whether endogenous ESR1 in N42 hypothalamic cells mediates E 2 -stimulated aromatase expression. As shown in Figure 9 , A and B, siRNA knockdown of Esr1 in N42 hypothalamic cells abolished induction of aromatase mRNA levels and enzyme activity by E 2 (10 À7 M) treatment. The knockdown of Esr1 was confirmed by real-time RT-PCR and IB (Fig. 9, C and D) .
DISCUSSION
Aromatase deficiency in humans disrupts normal gonadotropin regulation and libido [6] . Likewise, Cyp19a1KO mice exhibit disrupted reproductive behavior, including defective lordosis (females), low copulatory behavior, reduced sexual interest in the opposite sex, and deficiency in pup care [36] [37] [38] [39] . The gonadotropin secretion profile is also disrupted in Cyp19a1 KO mice, which have increased luteinizing hormone, follicle-stimulating hormone, testosterone, and prolactin, decreased E 2 , and unchanged dihydrotestosterone (DHT) [6, 18] . The reproductive phenotypes manifested in Cyp19a1 KO mice are similar to those observed in Esr1 knockout mice [1, 2, 40, 41] , suggesting that aromatase and ESR1 are important in mediating reproductive behavior controlled by the brain, and in particular by the hypothalamus. Aromatase is expressed primarily in gonads and the brain [3, 6, 14] . Loss of local E 2 synthesis in the brain likely leads to the hormonal and behavioral phenotypes observed in aromatasedeficient humans and mice. In fact, alterations in brain aromatase expression have been directly linked to changes in sexual behavior in birds, rodents, sheep, and humans [6, 38, 39, 42, 43] .
Gonadectomy reduces aromatase expression and enzyme activity in the brain; however, treatment of gonadectomized animals with testosterone or E 2 markedly restores aromatase activity in several brain regions, including the preoptic/ hypothalamic area in birds and mammals [17, 21, [23] [24] [25] [26] . Moreover, the positive effects of testosterone on copulatory behavior can be blocked by inhibiting ESR1 action or aromatase. These observations suggest that not only ESR1, but also endogenously synthesized E 2 may play a role in the regulation of aromatase in the brain. On the contrary, DHT by itself has almost no effect on aromatase expression, suggesting that testosterone needs to be converted to E 2 to exert its effects on the brain [14, 23, 24, 40] . Consistent with these published data, we did not observe any time-or dose-dependent effect of DHT on aromatase mRNA expression or enzyme activity in hypothalamic neuronal cell lines (data not shown).
Estradiol has been reported to alternately increase or decrease brain aromatase expression and enzyme activity [17, 25, 27, 28, 44, 45] . These reports are consistent with our current findings that E 2 showed a biphasic stimulatory effect on aromatase mRNA levels and enzyme activity in hypothalamic cells. Moreover, our observation that E 2 -induced aromatase expression is dependent on the presence of ESR1 is also consistent with the findings of other groups employing similar E 2 concentrations under various in vivo and in vitro settings [28, [46] [47] [48] [49] .
The varying intracellular concentration of E 2 and possible alterations in the composition of the multimeric transcriptional complex at promoter I.f over time may explain the mechanism of biphasic response observed in this study. These considerations will be investigated as future directions.
Estradiol is synthesized in specific brain regions, including the hypothalamus and hippocampus, where tissue E 2 concentrations are found to be higher than circulating E 2 levels [1, 2, [46] [47] [48] [49] [50] . Because E 2 is synthesized within the cytoplasm of neurons in these regions, it is possible that supraphysiologic levels of E 2 mediate intracrine and paracrine effects on neighboring steroidogenic and neuronal cells, comparable to effects of supraphysiologic quantities of endocrine E 2 supplied FIG. 9. ESR1 mediates E 2 -stimulated aromatase mRNA expression in N42 hypothalamic cells. N42 hypothalamic cells were transfected with Esr1 siRNA or with nonspecific siRNA as a negative control (NS) and were cultured for an additional 48 h. A) Aromatase mRNA levels were analyzed by real-time RT-PCR in the presence or absence of E 2 (10 À7 M; 6 h). Aromatase mRNA levels were normalized to Gapdh mRNA levels. The results are expressed as the mean 6 SEM (n ¼ 3; **P , 0.01, ANOVA. B) Aromatase activity assays were performed in the presence or absence of E 2 (10 À7 M; 6 h). The results are expressed as the mean 6 SEM (n ¼ 3); **P , 0.01, ANOVA. Aromatase enzyme activity in N42 neuronal line treated with the aromatase enzyme inhibitor LET was undetectable (data not shown). Real-time RT-PCR (C) and IB (D) were performed to measure Esr1 mRNA and protein levels, respectively. Actin was used as a loading control. The IB figure represents one of three independently performed experiments. Real-time RT-PCR results are expressed as the mean 6 SEM (n ¼ 3), and Gapdh was used as a loading control. **P , 0.01, ANOVA. Representative results from three independent experiments are shown.
to the brain via the bloodstream [6, 46, 48] . This notion has been raised by numerous studies, which have reported that the biologic effects of E 2 could only be triggered by concentrations in the nanomolar to micromolar range [5, 6, 27, 28, [46] [47] [48] [49] . In this study, we used micromolar to nanomolar (10 À7 to 10 À9 ) E 2 concentrations. Although these E 2 concentrations are much higher than those observed in the plasma, they might appropriately mimic the local conditions in target areas of the brain.
Interestingly, it was reported that E 2 induces aromatase expression in the VMH but not in the medial preoptic area, and there is less frequent ESR1 and aromatase colocalization compared with the VMH [14, 41, 42, 51] . These findings suggest a critical in vivo role for ESR1 in regulating aromatase expression [14, 41, 42, 51] . In parallel with these findings, we observed that E 2 induced aromatase mRNA expression and enzyme activity in N42 but not in N38 hypothalamic cells, and the N38 cells expressed markedly lower levels of ESR1 compared with N42 cells (Figs. 1 and 2) . It is likely that basal aromatase expression in N42 cells may be regulated by locally produced E 2 , because basal aromatase expression was suppressed by an estradiol antagonist (Figs. 1A and 3A) .
The developmental and tissue-, region-, and neuron-specific expression of aromatase in the brain has been reported to be transcriptionally regulated through promoter I.f, with the region 202 bp upstream of the transcriptional initiation site being essential and sufficient for basal transcriptional activity in cultured neurons [12, 52] . Our current findings are largely in agreement with these previous findings (Fig. 4A) .
Honda et al. [12] demonstrated interactions between nuclear proteins and several sequences within the nt À200/À1 region of promoter I.f. Of these sequences, nt À171/À147, nt À136/À109, and nt À84/À60 were reported to form complexes exhibiting a similar pattern of mobility on gel shift assays, suggesting that all three sites bind to the same transcription factor(s). Indeed, these three sequences were shown previously to interact with an identical nuclear factor whose molecular mass was indicated to be around 42 kDa [12] , but the identity of these nuclear factors has never been revealed. Interestingly, we showed that both JUN and ESR1 bound to AP-1 motifs within the region that encompasses these first two sequences. We have not characterized binding of JUN or ESR1 to the nt À84/À60 sequence, but we have identified two putative AP-1 motifs within this region. Since the molecular mass of JUN is approximately 42 kDa, we postulate that the unknown transcription factor in the previous study was JUN. The expression profile of JUN in the brain of mice and rats is similar to that of aromatase, with a transient peak followed by a gradual decrease during fetal development [14, 35, 53] . Thus, these data collectively suggest that JUN may be one of the critical transcription factors responsible for regulating prenatal aromatase expression in the fetal brain.
In summary, we demonstrated a nonclassical action of ESR1 in mediating estrogen-dependent regulation of aromatase expression in hypothalamic neuronal cell lines. Our future directions include verification of these findings using in vivo models. We also plan to further investigate the in vitro and in vivo effects of other hormones (e.g., progesterone) on aromatase expression and activity to elucidate the molecular mechanisms mediating local E 2 synthesis in the hypothalamus.
